SUNPHARMA Stock Overview
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
NewNotes are coming soon
Sun Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,051.70 |
| 52 Week High | ₹1,070.95 |
| 52 Week Low | ₹789.90 |
| Beta | 0.40 |
| 1 Month Change | 5.02% |
| 3 Month Change | 1.46% |
| 1 Year Change | 26.03% |
| 3 Year Change | 151.87% |
| 5 Year Change | 88.66% |
| Change since IPO | 51,634.03% |
Recent News & Updates
Recent updates
These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09
Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jul 12Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Apr 28Are Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Investors Paying Above The Intrinsic Value?
Apr 09Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.00
Feb 02Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Using Too Much Debt?
Feb 02Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jan 19Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Dec 27Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly
Nov 04Here's Why I Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Oct 21Calculating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Sep 27This Is Why Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 24Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has Announced That It Will Be Increasing Its Dividend To ₹2.00
Aug 06Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Shares Could Be 23% Above Their Intrinsic Value Estimate
May 31What Type Of Shareholders Make Up Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Share Registry?
Mar 08How Does Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Fare As A Dividend Stock?
Feb 22Interested In Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming ₹5.50 Dividend? You Have Three Days Left
Feb 04
Sun Pharmaceutical Industries Limited Just Beat EPS By 32%: Here's What Analysts Think Will Happen Next
Feb 01Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Jan 20Don't Ignore The Fact That This Insider Just Sold Some Shares In Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jan 05These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 28Have Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Insiders Been Selling Their Stock?
Dec 12Do Insiders Own Lots Of Shares In Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)?
Dec 07Here's Why We Think Sun Pharmaceutical Industries's (NSE:SUNPHARMA) Statutory Earnings Might Be Conservative
Nov 22Shareholder Returns
| SUNPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 0.2% | -1.3% | -3.8% |
| 1Y | 26.0% | -4.1% | -0.05% |
Return vs Industry: SUNPHARMA exceeded the Indian Pharmaceuticals industry which returned -4.1% over the past year.
Return vs Market: SUNPHARMA exceeded the Indian Market which returned -0% over the past year.
Price Volatility
| SUNPHARMA volatility | |
|---|---|
| SUNPHARMA Average Weekly Movement | 2.2% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.3% |
Stable Share Price: SUNPHARMA is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: SUNPHARMA's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 38,000 | Dilip Shanghvi | https://www.sunpharma.com |
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products.
Sun Pharmaceutical Industries Limited Fundamentals Summary
| SUNPHARMA fundamental statistics | |
|---|---|
| Market Cap | ₹2.50t |
| Earnings (TTM) | ₹41.05b |
| Revenue (TTM) | ₹410.24b |
61.5x
P/E Ratio6.2x
P/S RatioIs SUNPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUNPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹410.24b |
| Cost of Revenue | ₹113.13b |
| Gross Profit | ₹297.11b |
| Other Expenses | ₹256.06b |
| Earnings | ₹41.05b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Jan 31, 2023
| Earnings per share (EPS) | 17.11 |
| Gross Margin | 72.42% |
| Net Profit Margin | 10.01% |
| Debt/Equity Ratio | 6.8% |
How did SUNPHARMA perform over the long term?
See historical performance and comparison